Primary Endpoint Met In Phase 2 Trial Of Daclizumab In Patients With Relapsing Multiple Sclerosis
Medical News Today Tue, 13 Mar 2007 0:13 AM PDT
Biogen Idec, Inc. (Nasdaq: BIIB) and PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced today that the ongoing CHOICE trial, a Phase 2, randomized, double-blind, placebo-controlled trial of daclizumab, met its primary endpoint in relapsing multiple sclerosis (MS) patients being treated with interferon beta. [click link for full article]

Two tell kids how MS steals victims' health The Jersey Journal Mon, 12 Mar 2007 11:08 PM PDT Nine years ago, when she was 31, doctors diagnosed Bayonne's Denise Ripp as having multiple sclerosis. Her symptoms were numbness, fatigue and dizziness. "Sometimes you can walk into walls," she said.